Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Meta-Analysis of Promoter Methylation in Eight Tumor-Suppressor Genes and Its Association With the Risk of Thyroid Cancer Publisher Pubmed



Khatami F1 ; Larijani B2 ; Heshmat R1 ; Keshtkar A3 ; Mohammadamoli M2 ; Teimooritoolabi L4 ; Nasiri S5 ; Tavangar SM6
Authors

Source: PLoS ONE Published:2017


Abstract

Promoter methylation in a number of tumor-suppressor genes (TSGs) can play crucial roles in the development of thyroid carcinogenesis. The focus of the current meta-analysis was to determine the impact of promoter methylation of eight selected candidate TSGs on thyroid cancer and to identify the most important molecules in this carcinogenesis pathway. A comprehensive search was performed using Pub Med, Scopus, and ISI Web of Knowledge databases, and eligible studies were included. The methodological quality of the included studies was evaluated according to the Newcastle Ottawa scale table and pooled odds ratios (ORs); 95% confidence intervals (CIs) were used to estimate the strength of the associations with Stata 12.0 software. Egger’s and Begg’s tests were applied to detect publication bias, in addition to the “Metatrim” method. A total of 55 articles were selected, and 135 genes with altered promoter methylation were found. Finally, we included eight TSGs that were found in more than four studies (RASSF1, TSHR, PTEN, SLC5A, DAPK, P16, RARβ2, and CDH1). The order of the pooled ORs for these eight TSGs from more to less significant was CDH1 (OR = 6.73), SLC5 (OR = 6.15), RASSF1 (OR = 4.16), PTEN (OR = 3.61), DAPK (OR = 3.51), P16 (OR = 3.31), TSHR (OR = 2.93), and RARβ2 (OR = 1.50). Analyses of publication bias and sensitivity confirmed that there was very little bias. Thus, our findings showed that CDH1 and SCL5A8 genes were associated with the risk of thyroid tumor genesis. © 2017 Khatami et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Other Related Docs
5. Personalized Treatment Options for Thyroid Cancer: Current Perspectives, Pharmacogenomics and Personalized Medicine (2019)
6. A Review of Driver Genetic Alterations in Thyroid Cancers, Iranian Journal of Pathology (2018)
9. Genetic and Epigenetic of Medullary Thyroid Cancer, Iranian Biomedical Journal (2018)
10. Liquid Biopsy As a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations, International Journal of Molecular and Cellular Medicine (2019)
11. Pi3k/Akt Pathway and Its Mediators in Thyroid Carcinomas, Molecular Diagnosis and Therapy (2016)
13. Molecular Biomarkers of Anaplastic Thyroid Carcinoma, Current Molecular Medicine (2017)
14. Liquid Biopsy in Thyroid Cancer: New Insight, International Journal of Hematology-Oncology and Stem Cell Research (2018)